<sup>192</sup>Ir近距离治疗在局部复发非小细胞肺癌中的应用

doi:10.3760/cma.j.cn113030-20200817-00419

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To evaluate the clinical efficacy and adverse events of ¹⁹²Ir high-dose rate brachytherapy (HDR-BT) in the treatment of locally recurrent non-small cell lung cancer (NSCLC). Methods Clinical data of 22 cases of recurrent NSCLC after radiotherapy admitted to our hospital from September 2013 to March 2018 were retrospectively analyzed. ¹⁹²Ir HDR-BT was adopted for reradiotherapy. The prescription dose was 30Gy for 1 fraction. CT scan was reviewed every 1 month in the first 3 months after treatment and every 3 months after 3 months. Local control rate and adverse events were evaluated. The 1-and 2-year overall survival (OS) rates of re-treatment after relapse were calculated. Results All the 22 patients completed the treatment successfully. The 1-, 3-and 6-month complete response (CR) rates were 9%, 14% and 14%, 82%, 82% and 82% for the partial response (PR) rates, 5%, 0% and 0% for the stable disease (SD) rates, 5%, 5% and 5% for the progressive disease (PD) rates, 91%, 96% and 96% for the Objective response rates (ORR), respectively. The 1-and 2-year OS rates of re-treatment after relapse were 59% and 27%. Five patients (23%) experienced acute radiation-induced pneumonitis (3 cases of grade 1 and 2 cases of grade Ⅱ), 4 cases (18%) of radiation-induced bone marrow suppression (3 cases of grade I leukopenia and 1 case of grade I thrombocytopenia) and 1 case of postoperative pneumothorax. All these adverse events were mitigated after symptomatic treatment.Conclusion ¹⁹²Ir HDR-BT is an efficacious and safe treatment of locally recurrent NSCLC.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Key words： Locally recurrent,lung neoplasm/brachytherapy Treatment outcome Adverse event

Received: 17 August 2020

Corresponding Authors: Sun Yunchuan, Email:13932719095@163.com

Cite this article:

. Application of ¹⁹²Ir brachytherapy in locally recurrent non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(8): 775-779.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200817-00419 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I8/775

[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI:10.3322/caac.21338.
[2] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. DOI:10.3322/caac.21262.
[3] 吴敬波,张建文,向莉,等. CT引导下周围型肺癌插植三维后装放疗初探[C]//中华医学会第九次全国放射肿瘤治疗学学术会议论文集. 北京:中华医学会放射肿瘤治疗学分会,2012:399-400.
Wu JB, Zhang JW, Xiang L, et al. Preliminary study on CT guided three-dimensional brachytherapy for peripheral lung cancer[C]. Proceedings of the 9^th national conference on radiation oncology of Chinese Medical Association,Beijing:Radioactive Oncology Therapy Branch of the Chinese Medical Association, 2012:399-400.
[4] 尹晓明,孙云川,胡婷婷,等.¹⁹²Ir高剂量率近距离治疗在结直肠癌术后复发肺内寡转移治疗的初步应用[J]. 中华放射医学与防护杂志,2019, 39(11):833-836. DOI:10.3760/cma.j.issn.0254-5098.2019.11.006.
Yin XM, sun YC, Hu TT, et al. Preliminary application of ¹⁹²Ir high dose rate brachytherapy in the treatment of postoperative recurrent pulmonary oligo metastasis of colorectal cancer[J]. Chin J Radiol Med Prot, 2019, 39(11):833-836. DOI:10.3760/cma.j.issn.0254-5098.2019.11.006.
[5] Ohguri T, Imada H, Yahara K, et al. Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer:a potential modality for inducing long-term survival in selected patients[J]. Lung Cancer, 2012, 77(1):140-145. DOI:10.1016/j.lungcan.2012.02.018.
[6] Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(13):2181-2190. DOI:10.1200/JCO.2009.26.2543.
[7] Trovo M, Minatel E, Durofil E, et al. Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2014, 88(5):1114-1119. DOI:10.1016/j.ijrobp.2014.01.012.
[8] 徐秀理,胡宗涛,芦东徽,等. 局部复发非小细胞肺癌SRT再程放疗近期疗效及不良反应观察[J]. 中华放射肿瘤学杂志,2019, 28(7):495-498. DOI:10.3760/cma.j.issn.1004-4221.2019.07.004.
Xu XL, Hu ZT, Lu DH, et al. Observation of short-term clinical efficacy and adverse reactions with stereotactic radiotherapy in locally recurrent non-small cell lung cancer[J]. Chin J Radiat Oncol, 2019, 28(7):495-498. DOI:10.3760/cma.j.issn.1004-4221.2019.07.004.
[9] Xiang L, Zhang JW, Lin S, et al. Computed Tomography-guided interstitial high-dose-rate brachytherapy in combination with regional positive lymph node intensity-modulated radiation therapy in locally advanced peripheral non-small cell lung cancer:a phase 1 clinical trial[J]. Int J Radiat Oncol Biol Phys,2015, 92(5):1027-1034. DOI:10.1016/j.ijrobp.2015.04.019.
[10] Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage Ⅰ nonsmall cell lung carcinoma:clinical outcomes in 245 subjects in a Japanese multⅡnstitutional study[J]. Cancer, 2004, 101(7):1623-1631. DOI:10.1002/cncr.20539.
[11] Kim MS, Kim W, Park IH, et al. Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery[J]. Radiat Oncol J, 2015, 33(4):265-275. DOI:10.3857/roj.2015.33.4.265.
[12] Manning MA, Zwicker RD, Arthur DW, et al. Biologic treatment planning for high-dose-rate brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2001, 49(3):839-845. DOI:10.1016/s0360-3016(00)01453-x.
[13] Roses RE, Datta J, Czerniecki BJ. Radiation as immunomodulator:implications for dendritic cell-based immunotherapy[J]. Radiat Res, 2014, 182(2):211-218. DOI:10.1667/RR13495.1.
[14] Wattenberg MM, Fahim A, Ahmed MM, et al. Unlocking the combination:potentiation of radiation-induced antitumor responses with immunotherapy[J]. Radiat Res, 2014, 182(2):126-138. DOI:10.1667/RR13374.1.
[15] Okamoto Y, Murakami M, Yoden E, et al. Reirradiation for locally recurrent lung cancer previously treated with radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2002, 52(2):390-396. DOI:10.1016/s0360-3016(01)02644-x.
[16] 杨肖华,黄新宇,汪国祥等. CT引导下经皮肺穿刺活检术并发症的影响因素分析[J]. 介入放射学杂志,2013, 22(8):658-662. DOI:10.3969/j.issn.1008-794X.2013.08.011.
Yang XH, Huang XY, Wang GX, et al. Complications of CT-guided percutaneous lung puncture biopsy:an analysis of influencing factors[J]. J Int Radiol, 2013,22(8):658-662. DOI:10.3969/j.issn.1008-794x.2013.08.011.
[17] 杨波,孙小杨,庞皓文,等. 肺癌插植放疗中插植针排列规则对肺受量影响研究[J]. 中华放射肿瘤学杂志, 2017, 26(12):1417-1420. DOI:10.3760/cma.j.issn.1004-4221.2017.12.013.
Yang B, Sun XY, Pang HW, et al. Effect of needle arrangement on the lung dose in interstitial brachytherapy for lung cancer[J]. Chin J Radiat Oncol, 2017, 26(12):1417-1420. DOI:10.3760/cma.j.issn.1004-4221.2017.12.013.